Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Company Deals

Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio

Fineline Cube Apr 8, 2026
Company Deals

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Fineline Cube Apr 8, 2026
Company Drug

Lee’s Pharma’s Socazolimab Approved by NMPA for ES-SCLC First-Line Treatment

Fineline Cube Aug 1, 2025

Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced that its in-licensed programmed-death ligand 1 (PD-L1) monoclonal...

Company Deals

BrightGene and CR Sanjiu Collaborate on BGM0504 Injection Development and Commercialization

Fineline Cube Aug 1, 2025

China-based BrightGene Bio-Medical Technology Co., Ltd. (SHA: 688166) and its affiliated companies announced a collaboration...

Company

AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth

Fineline Cube Aug 1, 2025

US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing...

Company

BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook

Fineline Cube Aug 1, 2025

US major Bristol-Myers Squibb (BMS; NYSE: BMY) reported Q2 2025 financial results, revealing total revenues...

Policy / Regulatory

China’s NHSA Issues Rules for Instant Settlement of Medical Insurance Funds

Fineline Cube Aug 1, 2025

China’s National Healthcare Security Administration (NHSA) has issued the “Interim Administrative Rules for Instant Settlement...

Company Deals

Hybio and BrightGene Partner on Peptide Raw Material Supply for Global Drug Commercialization

Fineline Cube Aug 1, 2025

China-based Hybio Pharmaceutical Co., Ltd. (SHE: 300199) and China-based BrightGene Bio-Medical Technology Co., Ltd. (SHA:...

Company Drug

BeOne Medicines’ BGB-16673 Granted PRIME Designation by EMA for Waldenström’s Macroglobulinemia

Fineline Cube Aug 1, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced on July 31, 2025,...

Company Drug

Neurodawn’s Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection

Fineline Cube Aug 1, 2025

China-based Neurodawn Pharmaceutical Co., Ltd.’s wholly-owned subsidiary, Fuzhou Ningdan Rongkang Biomedical Technology Co., Ltd. (Ningdan...

Policy / Regulatory

NMPA Seeks Public Feedback on Draft Regulations for Internet Drug and Medical Device Information Services

Fineline Cube Aug 1, 2025

On July 31, 2025, China’s National Medical Products Administration (NMPA) commenced soliciting public comments on...

Company Drug

Haisco’s Ciprofol NDA Accepted by FDA: A Milestone for Chinese Anesthesia Innovation

Fineline Cube Aug 1, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that the New Drug Application (NDA)...

Company Drug

AstraZeneca’s Ultomiris Gains NMPA Approval for Neuromyelitis Optica Spectrum Disorder

Fineline Cube Aug 1, 2025

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Chipscreen’s Next-Gen Brain-Penetrant Aurora B Inhibitor CS231295 Gains FDA Clearance for Advanced Solid Tumors

Fineline Cube Aug 1, 2025

On July 31, 2025, the investigational new drug (IND) application for Shenzhen Chipscreen Biosciences Co.,...

Company Drug

Hengrui Receives Clinical Clearance for HRS-5041 in Prostate Cancer Treatment

Fineline Cube Aug 1, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance from...

Company Deals

Porton Advanced and Cellstore Partner to Optimize Cell Therapy Drug Cryopreservation

Fineline Cube Jul 31, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Porton Advanced Solutions Ltd. and Cellstore announced today...

Company Deals

ImmuneOnco Receives $10M Milestone Payment from Instil Bio for IMM2510/IMM27M Collaboration

Fineline Cube Jul 31, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced today that it has received a...

Company Deals

Luoxin Pharmaceutical Transfers Equity Stake to Shanghai Pharma for RMB 415 Million

Fineline Cube Jul 31, 2025

China-based Luoxin Pharmaceutical Group Co., Ltd. (SHE: 002793) announced that its subsidiary, Shandong Luoxin Pharmaceutical...

Company Deals

Sino Biopharmaceutical on Track to Receive $300M Milestone Payment for PD-1/VEGF Antibody Deal

Fineline Cube Jul 31, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the out-licensing collaboration between its subsidiary...

Company Deals

Walvax Expands Rights to Notitia’s Gut Microbiota Therapy in Greater China

Fineline Cube Jul 31, 2025

Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that an amendment...

Company Drug

Sanofi’s SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma

Fineline Cube Jul 31, 2025

French pharmaceutical major Sanofi (NASDAQ: SNY) reported that the U.S. Food and Drug Administration (FDA)...

Company Deals

Sandoz to Acquire Evotec’s Biologics Unit for $300 Million Expansion

Fineline Cube Jul 31, 2025

Switzerland-headquartered Sandoz (SWX: SDZ) announced that it has signed a non-binding term sheet with Germany’s...

Posts pagination

1 … 101 102 103 … 647

Recent updates

  • Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests
  • Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications
  • Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data
  • Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders
  • Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Others

Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.